All In Biotech

Drug Trial Radar · NCT04150887

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Actual

Start

Dec 23, 2019

Primary completion

May 15, 2027

Study completion May 15, 2027

Sponsor

Lead sponsor
OncoVerity, Inc.Industry
Sponsor type
Industry
Collaborators
argenx; Janssen Research & Development, LLC
First posted
Nov 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • CusatuzumabDrug

    Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.

  • AzacitidineDrug

    Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.

  • VenetoclaxDrug

    Venetoclax will be administered orally and the dose will ramp-up to 400 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of SafetyTime frame: Up to 42 months

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Norton Cancer Institute

    Louisville, Kentucky

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Weill Cornell Medicine

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Vermont

    Burlington, Vermont

  • Wisconsin Medical Center

    Milwaukee, Wisconsin

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • University of Toronto

    Toronto, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Universitaetsklinik Hamburg-Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Leipzig

    Leipzig, Germany

  • Klinikum der Universitaet Muenchen

    München, Germany

  • Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

    Lodz, Poland

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland

  • INSELSPITAL, Universitätsspital Bern

    Bern, Switzerland

  • Kantonsspital St.Gallen

    Sankt Gallen, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.